Boothbay Fund Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-53,506
Closed -$257K 1831
2023
Q4
$257K Sell
53,506
-46,494
-46% -$285K 0.01% 1242
2023
Q3
$724K Buy
+100,000
New +$799K 0.02% 900
2019
Q2
Sell
-5,037
Closed -$56K 845
2019
Q1
$56K Buy
+5,037
New +$159K 0.01% 692
2018
Q4
Sell
-1,027
Closed -$39K 815
2018
Q3
$39K Buy
+1,027
New +$28.9K ﹤0.01% 751
2017
Q3
Sell
-774
Closed -$18K 727
2017
Q2
$18K Buy
+774
New +$15.2K ﹤0.01% 643

Other funds holding NVAX

Boothbay Fund Management's NVAX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Novavax (NVAX) in Q1 2024, closing a stake of 53,506 shares — an estimated $257K sold.

Boothbay Fund Management first reported a position in NVAX in Q2 2017 and held it in 5 quarters. The position peaked at $724K in Q3 2023. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 53,506 Novavax shares in Q1 2024, an estimated $257K.
  • Boothbay Fund Management first reported a position in Novavax in Q2 2017 and held it in 5 quarters.
  • Boothbay Fund Management's Novavax position peaked at $724K in Q3 2023.
  • 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.